← brief for 2026-08-10 · Slowing decline

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Trial No results yet Not peer reviewed

Key takeaways

This 5-year trial tests orforglipron, a GLP-1 drug taken as a pill, to see if it prevents heart attacks, strokes, and other problems in adults who have heart disease and/or chronic kidney disease. Half get the drug and half get a placebo. There are no results yet.

Who did this work

Run by Eli Lilly and Company. Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (Eli Lilly and Company)
Sites: Instituto de Investigaciones Clínicas Bahia Blanca · CONEXA Investigacion Clinica S.A. · Buenos Aires Macula S.A · CIPREC · Instituto Médico Especializado (IME) · Cicemo Srl

Source

Trial registration · ClinicalTrials.gov — CKD recruiting · 2026-08-06
https://clinicaltrials.gov/study/NCT07241390